Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Hepatology. 2017 Jul 18;66(3):953–968. doi: 10.1002/hep.29215

Figure 7. PTX3 expression and correlation with clinical parameters in patients with liver disease.

Figure 7

a) PTX3 hepatic gene expression in cirrhotic alcoholic liver disease patients (Cirrhotic) (n=5), patients with alcoholic hepatitis (AH) (n=30) compared with healthy controls (n=5) (*p<0,05; **p<0,01). b) PTX3 plasma levels were significantly increased in patients with compensated cirrhosis (n=5) and both mild (n=15) and severe AH (n=39), compare with healthy patients (n=8); *p<0,05 compare with controls; **p<0,01 compare with controls; $ p<0,01 compare with other groups. c) correlation of PTX3 plasma levels and hepatic gene expression in patients with AH (n=23). d) Representative picture of PTX3 immunohistochemistry in liver sections of cirrhotic alcoholic liver disease patients (x200 magnification). Correlation of PTX3 plasma level with disease severity score, e) Model for End-stage Liver Disease (MELD) score, f) Age, serum Bilirubin, INR, and serum Creatinine (ABIC) score in patients with AH (n=54). g) Correlation of LPS serum level and PTX3 plasma levels in patients with AH (n=40). h) Kaplan-Meier analysis showing prognostic 180 day mortality based on PTX3 plasma level in patients with AH (n=54). The cut-off with better sensitivity and specificity was identified as 10 ng/mL (p=0,004). Severe AH was defined as a MELD >21 and or ABIC >8.99.